Mammary analogue secretory carcinoma of a salivary gland of the hard palate with contralateral cervical lymph node metastases: A case report

Straub,Anton; Linz,Christian; Strobel,Sabrina; Hartmann,Stefan; Hohm,Julian; Fuchs,Andreas; Müller‑Richter,Urs; Kübler,Alexander; Brands,Roman

doi:10.3892/mco.2021.2389

Mammary analogue secretory carcinoma of a salivary gland of the hard palate with contralateral cervical lymph node metastases: A case report

Authors:
- Anton Straub
- Christian Linz
- Sabrina Strobel
- Stefan Hartmann
- Julian Hohm
- Andreas Fuchs
- Urs Müller‑Richter
- Alexander Kübler
- Roman Brands
View Affiliations

Affiliations: Department of Maxillofacial and Plastic Surgery of The University of Wuerzburg, D‑97070 Wuerzburg, Germany, Institute of Pathology of The University of Wuerzburg, D‑97080 Wuerzburg, Germany
Published online on: September 6, 2021 https://doi.org/10.3892/mco.2021.2389
Article Number: 226
Copyright: © Straub et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mammary analogue secretory carcinoma (MASC) is a rare malignant tumour of the salivary glands, with only few cases reported in the literature to date. Initial preoperative staging is crucial for all patients with an oral malignancy to visualize the tumour, detect lymph node or distant metastases and plan therapeutic interventions. In the case presented herein, radiological imaging revealed a tumour of the right hard palate with suspected positive contralateral lymph nodes. Therefore, local tumour resection comprising hemimaxillectomy and bilateral neck dissection was performed. The diagnosis of MASC was finally based on characteristic histopathological and immunohistochemical findings, such as S100 protein and mammaglobin positivity. The diagnosis of MASC may be challenging, as such findings lack specificity. To confirm the diagnosis, molecular genetic examinations may be performed to detect a highly specific ETV6‑NTRK3 fusion gene. Depending on the results of these examinations, surgery, alone or combined with adjuvant radiation or chemoradiation, is the recommended approach. In summary, MASC should be treated similarly to other low‑grade salivary gland tumours, such as acinic cell carcinoma, as they exhibit biological and histopathological similarities.

View Figures

View References

1	Skálová A, Vanecek T, Sima R, Laco J, Weinreb I, Perez-Ordonez B, Starek I, Geierova M, Simpson RH, Passador-Santos F, et al: Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: A hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 34:599–608. 2010.PubMed/NCBI View Article : Google Scholar
2	Seethala RR and Stenman G: Update from the 4th Edition of the World Health Organization classification of head and neck tumours: Tumors of the salivary gland. Head Neck Pathol. 11:55–67. 2017.PubMed/NCBI View Article : Google Scholar
3	Luk PP, Selinger CI, Eviston TJ, Lum T, Yu B, O'Toole SA, Clark JR and Gupta R: Mammary analogue secretory carcinoma: An evaluation of its clinicopathological and genetic characteristics. Pathology. 47:659–666. 2015.PubMed/NCBI View Article : Google Scholar
4	Majewska H, Skalova A, Stodulski D, Klimková A, Steiner P, Stankiewicz C and Biernat W: Mammary analogue secretory carcinoma of salivary glands: A new entity associated with ETV6 gene rearrangement. Virchows Arch. 466:245–254. 2015.PubMed/NCBI View Article : Google Scholar
5	Boliere C, Murphy J, Qaisi M, Manosca F and Fung H: Mammary analogue secretory carcinoma of the palate: Case report and review of the literature. Case Rep Dent. 2019(7416302)2019.PubMed/NCBI View Article : Google Scholar
6	Stevens TM and Parekh V: Mammary analogue secretory carcinoma. Arch Pathol Lab Med. 140:997–1001. 2016.PubMed/NCBI View Article : Google Scholar
7	Shah AA, Wenig BM, LeGallo RD, Mills SE and Stelow EB: Morphology in conjunction with immunohistochemistry is sufficient for the diagnosis of mammary analogue secretory carcinoma. Head Neck Pathol. 9:85–95. 2015.PubMed/NCBI View Article : Google Scholar
8	Patel KR, Solomon IH, El-Mofty SK, Lewis JS Jr and Chernock RD: Mammaglobin and S-100 immunoreactivity in salivary gland carcinomas other than mammary analogue secretory carcinoma. Hum Pathol. 44:2501–2508. 2013.PubMed/NCBI View Article : Google Scholar
9	Khalele BA: Systematic review of mammary analog secretory carcinoma of salivary glands at 7 years after description. Head Neck. 39:1243–1248. 2017.PubMed/NCBI View Article : Google Scholar
10	Skalova A: Mammary analogue secretory carcinoma of salivary gland origin: An update and expanded morphologic and immunohistochemical spectrum of recently described entity. Head Neck Pathol 7. 1 (Suppl 1):S30–S36. 2013.PubMed/NCBI View Article : Google Scholar
11	Luo Y, Kaz AM, Kanngurn S, Welsch P, Morris SM, Wang J, Lutterbaugh JD, Markowitz SD and Grady WM: NTRK3 is a potential tumor suppressor gene commonly inactivated by epigenetic mechanisms in colorectal cancer. PLoS Genet. 9(e1003552)2013.PubMed/NCBI View Article : Google Scholar
12	Boon E, Valstar MH, van der Graaf WTA, Bloemena E, Willems SM, Meeuwis CA, Slootweg PJ, Smit LA, Merkx MAW, Takes RP, et al: Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands. Oral Oncol. 82:29–33. 2018.PubMed/NCBI View Article : Google Scholar
13	Skálová A, Vanecek T, Majewska H, Laco J, Grossmann P, Simpson RH, Hauer L, Andrle P, Hosticka L, Branžovský J and Michal M: Mammary analogue secretory carcinoma of salivary glands with high-grade transformation: Report of 3 cases with the ETV6-NTRK3 gene fusion and analysis of TP53, β-catenin, EGFR, and CCND1 genes. Am J Surg Pathol. 38:23–33. 2014.PubMed/NCBI View Article : Google Scholar
14	Brierley J, Gospodarowicz M and Wittekind C: Head and Neck Tumours, Lip and Oral Cavity. In: TNM Classification of Malignant Tumours. 8th edition. Wiley-Blackwell, Toronto, pp17-54, 2017.
15	Chiosea SI, Griffith C, Assaad A and Seethala RR: Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands. Histopathology. 61:387–394. 2012.PubMed/NCBI View Article : Google Scholar
16	Connor A, Perez-Ordonez B, Shago M, Skálová A and Weinreb I: Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: Expanded morphologic and immunohistochemical spectrum of a recently described entity. Am J Surg Pathol. 36:27–34. 2012.PubMed/NCBI View Article : Google Scholar
17	Sethi R, Kozin E, Remenschneider A, Meier J, VanderLaan P, Faquin W, Deschler D and Frankenthaler R: Mammary analogue secretory carcinoma: Update on a new diagnosis of salivary gland malignancy. Laryngoscope. 124:188–195. 2014.PubMed/NCBI View Article : Google Scholar
18	Tokuzen N, Goda H and Nakashiro K: Locally advanced mammary analogue secretory carcinoma of the parotid gland. Int J Oral Maxillofac Surg. 48:865–868. 2019.PubMed/NCBI View Article : Google Scholar
19	Slootweg PJ, Hordijk GJ, Schade Y, van Es RJ and Koole R: Treatment failure and margin status in head and neck cancer. A critical view on the potential value of molecular pathology. Oral Oncol. 38:500–503. 2002.PubMed/NCBI View Article : Google Scholar
20	Weiss MH, Harrison LB and Isaacs RS: Use of decision analysis in planning a management strategy for the stage N0 neck. Arch Otolaryngol Head Neck Surg. 120:699–702. 1994.PubMed/NCBI View Article : Google Scholar
21	Shah JP, Candela FC and Poddar AK: The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity. Cancer. 66:109–113. 1990.PubMed/NCBI View Article : Google Scholar
22	Bier J: Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Recent Results Cancer Res. 134:57–62. 1994.PubMed/NCBI View Article : Google Scholar
23	Wolff KD, Al-Nawas B, Al-Sharif U, Beck J, Bikowski K, Bissinger O, Böhme P, Bönte-Hieronymus I, Bootz F, Bozzato A, et al: S3-Guidline regarding diagnosis and therapy of oral cancer. Oncology Guideline Program. AWMF, 2012 (In German). https://www.awmf.org/uploads/tx_szleitlinien/007-100OLl_S3-Diagnostik-Therapie-Mundhoehlenkarzinom_2021-03.pdf. Accessed March 2021.
24	Fukuhara R, Shinya T, Fukuma S, Ogawa N, Masaoka Y, Tanaka T, Marunaka H, Arioka T, Hiraki T, Kaji M and Kanazawa S: The diagnostic capacity of pre-treatment ¹⁸F-FDG PET/CT for predicting the extranodular spread of lymph node metastases in patients with oral squamous cell carcinoma. Acta Med Okayama. 74:123–128. 2020.PubMed/NCBI View Article : Google Scholar
25	Loo SW, Geropantas K, Beadsmoore C, Montgomery PQ, Martin WM and Roques TW: Neck dissection can be avoided after sequential chemoradiotherapy and negative post-treatment positron emission tomography-computed tomography in N2 head and neck squamous cell carcinoma. Clin Oncol (R Coll Radiol). 23:512–517. 2011.PubMed/NCBI View Article : Google Scholar
26	Ferrell JK, Mace JC and Clayburgh D: Contemporary treatment patterns and outcomes of salivary gland carcinoma: A national cancer database review. Eur Arch Otorhinolaryngol. 276:1135–1146. 2019.PubMed/NCBI View Article : Google Scholar
27	Amatu A, Sartore-Bianchi A and Siena S: NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 1(e000023)2016.PubMed/NCBI View Article : Google Scholar
28	Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, et al: Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 7:400–409. 2017.PubMed/NCBI View Article : Google Scholar
29	Jiang T, Wang G, Liu Y, Feng L, Wang M, Liu J, Chen Y and Ouyang L: Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers. Acta Pharm Sin B. 11:355–372. 2021.PubMed/NCBI View Article : Google Scholar
30	Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, et al: Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 378:731–739. 2018.PubMed/NCBI View Article : Google Scholar